U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H12ClN3O2
Molecular Weight 289.717
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-863233

SMILES

ClC1=CC2=C(OC3=C2N=C(NC3=O)[C@@H]4CCCN4)C=C1

InChI

InChIKey=JJWLXRKVUJDJKG-VIFPVBQESA-N
InChI=1S/C14H12ClN3O2/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9/h3-4,6,9,16H,1-2,5H2,(H,17,18,19)/t9-/m0/s1

HIDE SMILES / InChI

Description

BMS-863233, also known as XL413, is a potent and selective cell division cycle 7 (CDC7) kinase inhibitor with potential antineoplastic activity. BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
215.0 nM [IC50]
42.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BMS-63233
Primary
BMS-63233

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Prolonged treatment with BMS-863233 (XL413) during 3 days inhibited the cell proliferation (IC50 = 2685 nM), decreased cell viability (IC50 = 2142 nM) and elicited the caspase 3/7 activity (EC50 = 2288 nM) in human colorectal adenocarcinoma Colo-205 cells.